Exclusive Summary

• Clozapine's core patents have long expired globally, presenting zero IP barriers for market entry, and it is firmly listed on the WHO Model List of Essential Medicines.
• Affecting over 24 million schizophrenia patients worldwide with ~30% being treatment-resistant, Clozapine is the strict clinical necessity and the only guideline-recommended gold standard for out-of-control conditions.
• Due to mandatory blood monitoring (risk of agranulocytosis) and generic price wars, some regional supply chains are highly fragile, making supply stability a powerful market entry wedge.
• Offering the core 25mg and 50mg strengths for clinical dose titration, combined with China's manufacturing cost advantages, empowers overseas distributors to win high margins in local public tenders.